exposed

HIV Drug is 100 percent effective according to recent study

 

  Swiping left goes to next page (page 1 of 4)

 

A study published by the journal Clinical Infectious Diseases showed the controversial daily pill pre-exposure prophylaxis (PrEP) prevented HIV infection in all 657 patients who took it for two and a half years. 

The Food and Drug Administration (FDA) approved a fixed-dose treatment of emtricitabine and tenofovir for people who do not have HIV but may be at risk of contracting it back in 2012. Those antiviral drugs comprise PrEP, sold under the brand name Truvada, which can keep HIV infection at bay when an individual is exposed from injection drug use or unprotected sex.

“Our study is the first to extend the understanding of the use of PrEP in a real-world setting and suggests that the treatment may prevent new HIV infections even in a high-risk setting,” lead author Jonathan Volk, MD, MPH, physician and epidemiologist at Kaiser Permanente San Francisco Medical Center, said in a news release. “Until now, evidence supporting the efficacy of PrEP to prevent HIV infection had come from clinical trials and a demonstration project.”